All patients were subsequently treated with tacrolimus and patients who had not received induction therapy also received mycophenolate. A number of randomised trials of alemtuzumab in solid organ transplantation have been published. Basiliximab trade name simulect is a chimeric mousehuman monoclonal antibody to the. Immunosuppressive therapy can be categorised as induction therapy or maintenance therapy. Atg was given at a dosage of 1 mgkgday for 3 to 5 days. Basiliximab induction therapy allows delayed initiation of cyclosporine after cardiac transplantation without an increase in rejection and reduces the risk of postoperative renal dysfunction. There are three antibodies which are used for induction therapy. Induction therapy is widely used in kidney transplant recipients. In kidney recipients, basiliximab reduces acute rejection without increasing the incidence of adverse events, including infection and malignancy, when combined with standard dualor. Basiliximab in the therapy of acute rejection after organ. Patients receiving the drug should be managed in facilities equipped and staffed with laboratory and supportive medical resources. A prospective economic evaluation of basiliximab simulect.
Comparison of induction strategies in renal transplantation hinojosa page 9 what is the optimal induction agent in kidney transplant recipients. However, in recent years there has been an upward trend in the use of antibody. Initial immunosuppression with or without basiliximab. Induction therapy with two doses day 0 and day 4 of intravenous basiliximab as part of double or triple. Induction therapy with rabbit antithymocyte globulin. Increasing rates of infection after solid organ transplantation have been attributed to use of antilymphocyte induction therapies and intensification of regimens for maintenance immunosuppression. The physician should have complete information for the followup of the patient. Only physicians experienced in immunosuppression therapy and management of organ transplantation patients should prescribe this drug. We prospectively studied efficacy and safety outcomes of two 10.
The use of monoclonal antibodies in renal transplantation for induction therapy has been associated with a marked reduction in acute rejection rates with an impact on graft and patient survivals. Basiliximab basiliximab is a monoclonal antibody that. Selection of induction therapy in kidney transplantation hardinger. The use of basiliximab or rabbit antithymocyte globulin ratg for induction therapy has significantly reduced the incidence of acute rejection episodes after kidney transplantation. Antibody induction therapy has been shown to reduce acute rejection episodes in organ transplantation. Basiliximab simulect, a chimeric humanmurine monoclonal antibody, is indicated for the prevention of acute organ rejection in adult and paediatric renal transplant recipients in combination with other immunosuppressive agents. Nice is yet to evaluate the use of atg for induction therapy in renal transplantation.
Induction therapy mainly consists of early posttransplant. Rabbit antithymocyte globulin versus basiliximab in renal. Immunosuppressive induction therapy the use of induction therapy was introduced to reduce graft rejection in the immediate posttransplant period when the alloimmune response is most intense. Basiliximab or antithymocyte globulin for induction. Personalizing induction therapy in kidney transplantation. Cumulative organ survival for olt patients with and without. Basiliximab induction therapy given at days 0 and 4 after transplantation appears to be safe and costeffective for immunoprophylaxis in solid. Patients who undergo solid organ transplant require lifelong immunosuppression to prevent organ. Induction therapy in pediatric kidney transplantation.
In the 180 kidney transplant recipients, bpar episodes occurred in 14% of. To compare efficacy and safety of basiliximab versus antithymocyte globulin atg for induction therapy in kidney transplantation. Basiliximab is indicated for prophylaxis of kidney transplant. Evaluation of targeted basiliximab induction therapy in. Basiliximab induction therapy given at days 0 and 4 after transplantation appears to be safe and costeffective for immunoprophylaxis in solid organ transplant recipients, specifically in kidney and liver transplantation, when given in conjunction with dual or triple immunosuppressive therapy. Universal basiliximab bas induction therapy was discontinued at our center due to lack of efficacy versus no induction. Antilymphocyte therapies are widely used in organ transplantation for induction therapy and treatment of graft rejection. Starts before reperfusion of an organ during transplantation. The role of basiliximab induction therapy in organ transplantation. All patients received basiliximab or atg induction therapy. Simulect basiliximab dosing, indications, interactions. Induction with basiliximab in renal transplantation.
In the lancet, peter friend and the 3c study collaborative group report the results of the first part of the 3c studyan openlabel, randomised, multicentre study of alemtuzumab compared with basiliximab induction treatment, followed by sirolimus versus tacrolimus maintenance treatment, for the preservation of renal function in patients receiving kidney transplants. Induction therapy with rabbit antithymocyte globulin is preferable to induction with daclizumab in renal transplant recipients at high immunological risk. Monoclonal antibody therapy and renal transplantation mdpi. Pdf the role of basiliximab induction therapy in organ. Optimizing use of basiliximab in liver transplantation carlo b ramirez, adam bozdin, adam frank, warren maley, cataldo doriadepartment of surgery, thomas jefferson university, philadelphia, pa, usaabstract. It is used as induction therapy in kidney transplantation.
Induction immunosuppressives in renal transplantation. A literature search of the medline, embase, cbmdisc, and cochrane. Antibody induction therapy has not been part of standard immunosuppressive regimens in liver transplantation. Basiliximab vs lowdose thymoglobulin induction therapy in. Infectious complications of antilymphocyte therapies in. These trials noted lower mean acr rates in the basiliximab group compared with the standard therapy 23% vs 41%. The two most frequently prescribed agents are rabbit antihuman thymocyte immunoglobulin ratg, thymoglobulin, a lymphocytedepleting agent, and basiliximab, a monoclonal antiinterleukin 2 il2 receptor antibody 1. Basiliximab induction therapy given at days 0 and 4 after transplantation appears to be safe and costeffective for immunoprophylaxis in solid organ transplant recipients, specifically in kidney. Induction immunosuppression with basiliximab in heart. Influence of basiliximab induction therapy on long term outcome. In our center, 41 patients were enrolled in the multicenter trial chib201 in 199596 comparing basiliximab vs no induction therapy after renal transplantation. So far data is spares to prove this hypothesis and 10year follow up on basiliximab induction therapy is not available.
Efficacy and safety of antibody induction therapy in the current era of kidney transplantation. The role of basiliximab induction therapy in organ. Basiliximab vs lowdose thymoglobulin induction therapy in low risk kidney transplant patients. A rabbit antithymocyte polyclonal antibody or basiliximab, an interleukin2 r. Practically all kidney allograft recipients require immunosuppressive therapy to prevent rejection and loss of the allograft. A randomized, doubleblind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. The aim of this study was to determine the occurrence of biopsyproven acute rejection in lowimmunologic risk kidney transplant recipients according to the type of induction basiliximab vs lowdose of rabbit antithymocyte globulin ratg, 3. The potential benefits of lower incidence of acute rejec. Simulect basiliximab for injection rx only prescribing information warning only physicians experienced in immunosuppression therapy and management of organ transplantation patients should prescribe simulect basiliximab. Several trials have investigated basiliximab in the induction therapy of liver transplantation, in combination with calcineurin inhibitor and steroids, or in a triple regimen with the addition of azathioprine.
Tolerogenic immunosuppression for organ transplantation. Alemtuzumab induction therapy in solid organ transplantation. The role of induction therapy in renal transplantation. However, this induction therapy is not absolutely necessary, unless there is a high immunological risk or a higher risk of delayed. It is used to prevent rejection in organ transplantation. Background induction therapy reduces the frequency of acute rejection and delayed graft function after transplantation. The use of antibody induction therapy to delay cni initiation is.
It was the aim of this study to determine if basiliximab induction therapy serves to reduce the. It is typically used with other drugs after a kidney transplant. Induction therapy is an intensive immunosuppression regimen that is used for up to 2weeks around the time of transplant and may include polyclonal or monoclonal antibodies. Induction immunosuppression with basiliximab, combined with cyclosporine modified and. Optimizing use of basiliximab in liver transplantation trrm. Maintenance therapy starts immediately after transplant and continues for life. Randomised trials of alemtuzumab in solid organ transplantation. Induction therapy in solid organ transplantation 157 much experience in the use of antibody induction has been accumulated in kidney and heart transplantation. Induction therapy with basiliximab versus thymoglobulin in africanamerican kidney transplant recipients. Alemtuzumab induction therapy in kidney transplantation. Usual adult dose for organ transplant rejection prophylaxis. Section of organ transplantation and immunology, department of surgery, yale university school of medicine, new haven, ct.
It is used for induction immunoprophylaxis in solid organ transplantation. Basiliximab induction therapy in kidney transplantation. Timing of basiliximab induction and development of acute rejection. Immunosuppressive therapy for kidney transplant in. Basiliximab induction in kidney transplantation with donation after. Basiliximab is indicated for prophylaxis of kidney transplant rejection in the following patients for. The surgical technique of organ procurement is briefly described as follows.
1177 1246 471 674 1021 1530 355 1127 377 323 363 1153 1008 516 470 1555 971 574 943 900 1222 775 1000 1405 1340 199 940 935 243 931 1370 415 963 934 1221 1299